Regulatory – Page 20 – Alligator Bioscience

2018-07-19

Regulatory

Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody

Lund, Sweden, July 19, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...

2018-07-12

Regulatory

Positive data for our preclinical projects Significant events April-June• The ADC-1013 clinical phase I study performed by Janssen is ongoin ...

2018-04-26

Regulatory

Positive preclinical data for ATOR-1015 "Data provide strong support for our claims that ATOR-1015 is a next generation bispecific CTLA- ...

2018-03-22

Regulatory

Lund, Sweden, 22 March – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals f ...

2018-02-16

Regulatory

The Janssen collaboration continues, milestone payment of 6 MUSD triggered Significant events, October-December • Alligator Bioscience recor ...

2018-01-03

Regulatory

Lund, Sweden, 3 January, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...

2017-11-07

Regulatory

Lund, Sweden, 7 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...

2017-10-25

Regulatory

Three important collaborations in place. Results in November from ADC-1013 clinical phase I study. Significant events, July-September • Apte ...

2017-10-24

Regulatory

ALG.APV-527 – A novel bispecific antibody candidate being developed by Alligator Bioscience and Aptevo Therapeutics. Engineered to Eng ...